Development of an Electronic Portal Imaging Device Dosimetry Method

A Novel Approach for Position Verification and Dose Calculation through Local MVCT Reconstruction

Traditional positioning verification using cone-beam computed tomography (CBCT) may incur errors due to potential misalignments between the isocenter of CBCT and the treatment beams in radiotherapy. This study introduces an innovative method for verifying patient positioning in radiotherapy. Initially, the transmission images from an electronic portal imaging device (EPID) are acquired from 10 distinct angles. Utilizing the ART-TV algorithm, a sparse reconstruction of local megavoltage computed tomography (MVCT) is performed. Subsequently, this MVCT is aligned with the planning CT via a three-dimensional mutual information registration technique, pinpointing any patient-positioning discrepancies and facilitating corrective adjustments to the treatment setup. Notably, this approach employs the same radiation source as used in treatment to obtain three-dimensional images, thereby circumventing errors stemming from misalignment between the isocenter of CBCT and the accelerator. The registration process requires only 10 EPID images, and the dose absorbed during this process is included in the total dose calculation. The results show that our method's reconstructed MVCT images fulfill the requirements for registration, and the registration algorithm accurately detects positioning errors, thus allowing for adjustments in the patient's treatment position and precise calculation of the absorbed dose.

Using eclipse scripting to fully automate in-vivo image analysis to improve treatment quality and safety

PURPOSE

An automated, in-vivo system to detect patient anatomy changes and machine output was developed using novel analysis of in-vivo electronic portal imaging device (EPID) images for every fraction of treatment on a Varian Halcyon. In-vivo approach identifies errors that go undetected by routine quality assurance (QA) to compliment daily machine performance check (MPC), with minimal physicist workload.

METHODS

Images for all fractions treated on a Halcyon were automatically downloaded and analyzed at the end of treatment day. For image analysis, compared to first fraction, the mean difference of high-dose region of interest is calculated. This metric has shown to predict changes in planning treatment volume (PTV) mean dose. Flags are raised for: (Type-A) treatment fraction whose mean difference exceeds 10%, to protect against large errors, and (Type-B) patients with three consecutive fractions with mean exceeding ±3%, to protect against systematic trends. If a threshold is exceeded, a physicist is e-mailed, a report for flagged patients, for investigation. To track machine output changes, for all patients treated on a day, the average and standard deviations are uploaded to a QA portal, along with the reviewed MPC, ensuring comprehensive QA for the Halcyon. To guide clinical implementation, a retrospective study from November 2017 till December 2020 was conducted, which grouped errors by treatment site. This framework has been used prospectively since January 2021.

RESULTS

From retrospective data of 1633 patients (35 759 fractions), no Type-A errors were found and only 45 patients (2.76%) had Type-B errors. These Type-B deviations were due to head-and-neck weight loss. For 6 months of prospective use (345 patients), 13 patients (3.7%) had Type-B errors and no Type-A errors.

CONCLUSIONS

This automated system protects against errors that can occur in vivo to provide a more comprehensive QA. This fully automated framework can be implemented in other centers with a Halcyon, requiring a desktop computer and analysis scripts.